Guardant Health

YTD

ALL

Trade Guardant Health 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GH

Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection.

CEO

Helmy Eltoukhy

CEOHelmy Eltoukhy

Employees

2,506

Employees2,506

Headquarters

Palo Alto, California

HeadquartersPalo Alto, California

Founded

2011

Founded2011

Employees

2,506

Employees2,506

GH Key Statistics

Market cap

17.48B

Market cap17.48B

Price-Earnings ratio

-38.76

Price-Earnings ratio-38.76

Dividend yield

—

Dividend yield—

Average volume

2.25M

Average volume2.25M

High today

$134.00

High today$134.00

Low today

$130.19

Low today$130.19

Open price

$132.39

Open price$132.39

Volume

3.40M

Volume3.40M

52 Week high

$135.00

52 Week high$135.00

52 Week low

$40.36

52 Week low$40.36

Stock Snapshot

As of today, Guardant Health(GH) shares are valued at $131.70. The company's market cap stands at 17.48B, with a P/E ratio of -38.76.

During the trading session on 2026-06-19, Guardant Health(GH) shares reached a daily high of $134.00 and a low of $130.19. At a current price of $131.70, the stock is +1.2% higher than the low and still -1.7% under the high.

Trading activity shows a volume of 3.4M, compared to an average daily volume of 2.25M.

Over the past 52 weeks, Guardant Health(GH) stock has traded between a high of $135.00 and a low of $40.36.

GH News

TipRanks 23h

Guardant Health Shareholders Reject Executive Pay in Annual Vote

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

Simply Wall St 2d

What Guardant Health's New HER2-Positive NSCLC Companion Dx Approval Means For Shareholders

Earlier in June 2026, Guardant Health announced that the FDA approved its Guardant360 CDx liquid biopsy as a companion diagnostic for Boehringer Ingelheim’s HER...

Investing.com 3d

Guardant Health director Tariq Musa sells $15,102 in shares - Investing.com

...

Analyst ratings

89%

of 28 ratings

Buy

89.3%

Hold

3.6%

Sell

7.1%

People also own

Based on the portfolios of people who own GH. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.